Secondary malignancies after allogeneic stem cell transplantation are a known risk for stem cell recipients. The categories of new malignancies after transplant comprise lymphoproliferative disorders, hematologic malignancies (primarily therapy-related myelodysplastic syndrome and acute myeloid leukemia), and solid tumors. Some reviews summarize incidence and risk factors for these events. 1, 2 In contrast, malignant diseases arising from donor-derived cells are exceptionally rare (see below). We report a patient developing donor-derived myelodysplastic syndrome (MDS) almost 7 years after allogeneic transplantation for Ph þ chronic myeloid leukemia (CML) in 1998.
This female patient was diagnosed with CML in 1996 at the age of 35 years. After cytoreductive therapy with hydroxyurea and subsequent therapy with interferon alpha, the patient developed blast crisis and was treated with TAD induction therapy resulting in a second chronic phase. Allogeneic bone marrow transplantation (BMT) with an HLA-DRB1-mismatched female unrelated donor was performed in July 1998 in our center. Myeloablative conditioning consisted of busulfan and cyclophosphamide. For GvH-prophylaxis we used cyclosporine, short-course MTX, mycophenolate mofetil, and prednisolone. There were no significant complications in the immediate posttransplant period except CMV reactivation, which was controlled. There were no signs of acute GvHD. In 1999, the patient developed limited chronic GvHD (hepatic) which progressed to extensive chronic GvHD (cutaneous, conjunctival, oral, hepatic) . Further complications were recurring CMV reactivation, esophagitis and esophageal stenosis, and allergies to several antibiotics (vancomycin, clindamycin, penicillin) . In March 2004, corneal transplantation was performed. The quality of life was impaired because of extensive chronic GvHD (especially skin and oral mucosa).
The patient was reassessed in March 2005 due to thrombocytopenia and MDS was diagnosed. The patient was transferred to our center in May 2005 for further therapy. Bone marrow histology confirmed secondary MDS with no evidence of CD34 þ blasts by immune histochemistry. Cytogenetics showed a normal female karyotype. Additional FISH analysis presented an unconspicuous signal pattern, that is, there were no signs of typical chromosomal aberrations of MDS. Molecular testing for bcr/abl junction was negative.
Chimerism analysis by quantitative short tandem repeat (STR) DNA detection (15 systems, AmpFISTR Profiler Plus) revealed 499.5% donor proportion in bone marrow as well as in peripheral blood. The STR pattern of the recipient could not be detected in either compartments with a detection limit of 0.5%. These analyses were based on epidermal cell samples from the recipient and a blood sample from the donor. Our results confirm donor cellderived MDS almost 7 years after sex-matched allogeneic BMT.
We found approximately 20 cases of donor-cell leukemia reported in the literature, with six cases of MDS. [3] [4] [5] [6] [7] [8] It is interesting to note that most cases were sex-mismatched sibling transplants. There are several proposed hypotheses and/or contributing factors for the pathogenesis of donorcell leukemia as discussed and summarized by Komrokji et al 3 and Gopcsa and Paloczi. 
